Chabiotech Co.,Ltd. (KOSDAQ:085660)
8,360.00
+290.00 (3.59%)
Sep 1, 2026, 3:30 PM KST
Chabiotech Revenue
Chabiotech had revenue of 316.43B KRW in the quarter ending June 30, 2026, with 5.87% growth. This brings the company's revenue in the last twelve months to 1.31T, up 13.93% year-over-year. In the year 2025, Chabiotech had annual revenue of 1.27T with 21.36% growth.
Revenue (ttm)
1.31T
Revenue Growth
+13.93%
P/S Ratio
0.57
Revenue / Employee
4.72B
Employees
278
Market Cap
746.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27T | 223.20B | 21.36% |
| Dec 31, 2024 | 1.05T | 91.10B | 9.55% |
| Dec 31, 2023 | 953.95B | 109.37B | 12.95% |
| Dec 31, 2022 | 844.58B | 117.11B | 16.10% |
| Dec 31, 2021 | 727.48B | 62.76B | 9.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |
| AbClon | 5.31B |